Human Genome Says FDA Unlikely to Approve Bimonthly Zalbin Dose - Wall Street Journal

[INCIID News Feed]

<img alt="" height="1" width="1" />
Human Genome Says FDA Unlikely to Approve Bimonthly Zalbin Dose
Wall Street Journal
Human Genome Sciences Inc. said the Food and Drug Administration likely won&#39;t approve its effort to sell a hepatitis C drug in a dose that is taken every two weeks, expressing concern about the "risk benefit." The move comes two months after ...
Human Genome hep C drug OK unlikely at current doseReuters
Human Genome casts doubt on Zalbin approvalBusinessWeek
FDA may not approve Human Genome hepatitis C drugFood Consumer
FierceBiotech -International Business Times -MarketWatch (press release)
all 35 news articles &raquo;


More...